NEW YORK, May 14, 2019 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM) (“AXIM® Biotech”, “Axim”, or the “Company”), a world leader in cannabinoid research and development, today announced that the Company will be attending and presenting at Cannastocks 2019 Q1 Conference, taking place in New York on May 15, 2019.
AXIM’s Chief Executive Officer John W. Huemoeller II will bring his expertise to this year’s event, presenting on the Company’s updated business strategy, proprietary controlled-release technology and patent on all chewing gum containing cannabinoids, including the Company’s patented flagship chewing gum products. His presentation is scheduled to take place from 4:00 p.m. to 4:25 p.m. ET. The presentation will be available online to non-attendees as well for up to 90 days following.
“I look forward to introducing Cannastocks 2019 Q1 attendees to AXIM’s updated business strategy and educating them on what sets AXIM apart in cannabis research and development,” Huemoeller said. “The company has recently made a lot of advancements and updated its pipeline to reflect our shift in business goals while maintaining our reputation as an industry leader.”
AXIM® Biotech will be one of eight publicly traded companies presenting at the conference. Mr. Huemoeller will also be available for one-on-one meetings for those interested in learning more about AXIM while at the conference.
The Cannastocks 2019 Q1 Conference is a live-stream investor conference. The event will feature presentations by public companies, providing insight on innovation, consolidation, international expansion and specialization in the fast-growing cannabis industry.
A copy of AXIM’s management presentation can be found at: https://ir.aximbiotech.com/presentations.
For more information about the event, please visit: https://www.virtualinvestorconferences.com/events/event-details/cannastocks-2019-q1-conference.
To learn more about AXIM® Biotechnologies, Inc., please visit http://aximbiotech.com/.
About AXIM® Biotechnologies
AXIM® Biotechnologies, Inc. (AXIM) is a world leader in the research and development of cannabinoid-based pharmaceutical and nutraceutical products. Along with building a robust intellectual property portfolio, AXIM is focused on clinical development programs that bring more efficacy and/or lower side effects than existing alternatives and require small to medium budgets and timelines to bring to market which presents a high added-value to the pharmaceutical field.
AXIM's flagship products include MedChew® with dronabinol, which is planned to undergo a bioequivalence study to fast track through FDA as an alternative to approved Marinol; MedChew® RL, which is planned to undergo clinical trials for treatment of restless leg syndrome; and MedChew® Rx, a combination cannabidiol (CBD)/tetrahydrocannabinol (THC) functional, controlled-release chewing gum that is planned to undergo clinical trials for the treatment of pain and spasticity associated with Multiple Sclerosis (MS). For more information, please visit www.AXIMBiotech.com.
Public Relations Contact:
Chief Executive Officer
Corporate Contact Info:
North American Address:
45 Rockefeller Plaza, 20th Fl.
New York, NY 10111, USA
P. 844 294 6246
Industrieweg 40, Unit B4
3401 MA IJsselstein
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of AXIM Biotechnologies, Inc. to be materially different from the statements made herein.
AXIM® Biotechnologies does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA).